Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Differential expression of ISG20 in chronic hepatitis B patients and relation to interferon-alpha therapy response.

Lu X, Qin B, Ma Q, Yang C, Gong XY, Chen LM.

J Med Virol. 2013 Sep;85(9):1506-12. doi: 10.1002/jmv.23610.

PMID:
23794439
2.

Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus.

Xiao C, Qin B, Chen L, Liu H, Zhu Y, Lu X.

J Viral Hepat. 2012 Feb;19(2):e1-10. doi: 10.1111/j.1365-2893.2011.01471.x.

PMID:
22239505
3.

Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients.

Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ.

Virol J. 2012 Nov 16;9:274. doi: 10.1186/1743-422X-9-274.

4.
5.

Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.

Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA.

J Gastroenterol Hepatol. 2003 Jun;18(6):630-7.

PMID:
12753143
6.

Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.

Tang TJ, de Man RA, Kusters JG, Kwekkeboom J, Hop WC, van der Molen RG, Schalm SW, Janssen HL.

J Med Virol. 2004 Feb;72(2):215-22.

PMID:
14695662
7.

Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.

Rico MA, Quiroga JA, Subirá D, Castañón S, Esteban JM, Pardo M, Carreño V.

Hepatology. 2001 Jan;33(1):295-300.

PMID:
11124848
8.

Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients.

Zhu Y, Qin B, Xiao C, Lu X, Chen L.

Dig Dis Sci. 2012 Sep;57(9):2355-61. doi: 10.1007/s10620-012-2169-5.

PMID:
22585383
9.
11.

[Persistence of hepatitis B virus in children after interferon-alpha therapy despite the seroconversion in HBsAg/anti-HBs system].

Gregorek H, Dzierzanowska-Fangrat K, Woynarowski M, Jóźwiak P, Witkowska-Vogtt E, Wojda U, Syczewska M, Socha J, Madalińiski K.

Przegl Epidemiol. 2005;59(3):641-9. Polish.

PMID:
16433306
13.

Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.

Chung YH, Song BC, Lee GC, Shin JW, Ryu SH, Jung SA, Yoo K, Lee HC, Lee YS, Suh DJ.

Eur J Gastroenterol Hepatol. 2003 May;15(5):489-93.

PMID:
12702905
14.

High-dose interferon results in high HBsAg seroclearance in children with chronic hepatitis B infection.

Ertem D, Acar Y, Kotiloğlu Karaa E, Pehlivanoğlu E.

Turk J Pediatr. 2003 Apr-Jun;45(2):123-8.

PMID:
12921298
15.

Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B.

Alexopoulou A, Owsianka AM, Kafiri G, Dourakis SP, Carman WF, Hadziyannis SJ.

J Hepatol. 1998 Sep;29(3):345-51.

PMID:
9764979
17.

Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection.

Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, Kronenberger B, Piiper A.

J Viral Hepat. 2012 Feb;19(2):e58-65. doi: 10.1111/j.1365-2893.2011.01536.x.

PMID:
22239527
18.

Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha.

Ma JC, Wang LW, Li XJ, Liao YF, Hu XY, Gong ZJ.

Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):166-71.

19.
20.

Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.

Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Yu ML.

Antivir Ther. 2005;10(1):125-33.

PMID:
15751770

Supplemental Content

Support Center